Blog
Dec 20, 2024, 9:09 AM
At the 35th International Symposium on ALS/MND, held from December 6-8, 2024, at the Montreal Convention Center, AcuraStem Chief Scientific Officer Marcel van der Brug delivered a key presentation titled 'Development of an UNC13A Cryptic Exon Skipping Antisense Oligonucleotide as a Treatment for ALS.
Sep 9, 2024, 3:37 PM
At the RNA Leaders USA Congress, held September 4-5, 2024, at the San Diego Convention Center, AcuraStem CEO Sam Alworth delivered a key presentation titled 'Accelerating the Development of More Effective Treatments for ALS & FTD Using the iNeuroRx® Technology Platform.'
Aug 26, 2024, 3:46 PM
AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced the appointment of Dr. Rafael Renteria as Principal Scientist, hiPSC Platform.
Jun 21, 2024, 3:35 PM
AcuraStem’s Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan (Wen) Chang, will present at the 5th International Oligonucleotides and Peptides Conference (IOPC) on June 26, 2024, in Milan
Jun 18, 2024, 6:41 PM
AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced it has named Dr. Wen-Hsuan Chang as Associate Vice President of Discovery and Early Development
Jun 18, 2024, 6:32 PM
AcuraStem proudly sponsored the recent IgNight ALS event in Washington, D.C., a poignant evening dedicated to celebrating Steve Gleason and his profound contributions to the ALS community
Jun 3, 2024, 4:19 PM
AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced the expansion of its team with three new team members, bringing a fresh influx of expertise to its pioneering platform.
May 17, 2024, 6:24 PM
AcuraStem’s Associate Vice President, Dr. Wen-Hsuan (Wen) Chang, to Present at 3rd Annual ALS Drug Development Summit and Participate in Panel and Roundtable Discussions
Feb 27, 2024, 8:12 PM
AcuraStem CEO, Sam Alworth, will present on the company's trailblazing approach to amyotrophic lateral sclerosis (ALS) therapies at the MDA Clinical & Scientific Conference on March 4th.
Apr 10, 2023, 3:13 PM
AcuraStem's CEO, Sam Alworth, is set to present on the company’s latest advances in the development of a PIKFYVE antisense oligonucleotide (ASO) therapeutic for diverse forms of FTD (FTD) at the Alzheimer's Drug Discovery Foundation's (ADDF) Defeating Dementia Symposium on April 13.